Abstract | BACKGROUND:
N-methanocarbathymidine ( N-MCT) has previously been shown to be effective against lethal orthopoxvirus and herpes simplex virus type-1 infections in mice. In this investigation, the antiviral activity of N-MCT was assessed against herpes simplex virus type-2 (HSV-2) in BALB/c mice. METHODS: BALB/c mice were infected intranasally with a lethal challenge dose of HSV-2. N-MCT was administered orally twice daily to mice using doses of 0.01 to 100 mg/kg to determine effects on survival and on viral replication in organ and central nervous system (CNS) samples. RESULTS:
N-MCT provided significant protection from mortality even when treatments were delayed until 3 days after viral infection. Viral replication in organ and CNS samples from N-MCT-treated mice was reduced below the limit of detection after 4 days of treatment. CONCLUSIONS: These results indicated that low dose N-MCT treatment was more effective than acyclovir therapy. N-MCT may be effective against HSV disease in humans and is currently undergoing preclinical evaluation. In particular, its potential use as a combination therapy for HSV, with its differing metabolism from acyclovir, make it a promising compound to develop for human use.
|
Authors | Debra C Quenelle, Deborah J Collins, Terri L Rice, Aquilur Rahman, Robert Glazer |
Journal | Antiviral chemistry & chemotherapy
(Antivir Chem Chemother)
Vol. 22
Issue 3
Pg. 131-7
(Nov 17 2011)
ISSN: 2040-2066 [Electronic] England |
PMID | 22095521
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antiviral Agents
- (north)-methanocarbathymidine
- Thymidine
|
Topics |
- Administration, Oral
- Animals
- Antiviral Agents
(administration & dosage, pharmacology)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Female
- Herpes Simplex
(drug therapy, virology)
- Herpesvirus 2, Human
(drug effects)
- Humans
- Mice
- Mice, Inbred BALB C
- Survival Rate
- Thymidine
(administration & dosage, analogs & derivatives, pharmacology)
|